acquired
Stage
2008
Founded
1
Investors
About
Synaffix develops a clinical-stage platform technology for antibody-drug conjugates (ADCs) used primarily for cancer treatment. ADCs combine potent small molecule payloads with antibodies to target cancer cells while sparing healthy tissues, and Synaffix's technology enhances their effectiveness, tolerability, and safety compared to other ADC technologies.
Explore Synaffix B.V's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.